Physician profile
Mark St Martin
NPI 1922069061
$2,024.54
in general payments reported to CMS, 2019-2025
14 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $91.27 · 2021: $532 · 2022: $141 · 2023: $265 · 2024: $410 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,149.17 | 2019-2022 | |
| Novo Nordisk INC | $256.05 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $241.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $115.77 | 2023-2024 | |
| Amgen INC. | $70.91 | 2019-2024 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $50.39 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Vivus LLC | $33.91 | 2023-2024 | Qsymia |
| Abbott Laboratories | $24.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.36 | 2023 | |
| Dynavax Technologies Corporation | $15.79 | 2024 | Heplisav-B |
| Inari Medical, INC. | $13.37 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Biogen, INC. | $12.99 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.71 | 2023 | Seglentis |
| Teva Pharmaceuticals USA, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark St Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.